David S. Bredt, M.D., Ph.D.

In March 2011, Bredt was hired by Johnson and Johnson Pharmaceutical Group as Global Head of Neuroscience Discovery. In this role, he oversees preclinical biology and chemistry research. He also is in charge of clinical and preclinical biomarker and pharmacogenomics programs that support Johnson and Johnson's neuroscience franchise. His previous industry experience was with Eli Lilly and Company (2004-11) where he was Vice President of Integrative Biology and Vice President of Neuroscience Research. In these roles, Bredt's organizations have discovered numerous molecular candidates that are being studied as novel clinical therapies for pain, migraine, neurodegenerative, and neuropsychiatric disorders.

Bredt graduate summa cum laude in Chemistry at Princeton University in May 1986. He received his M.D. and Ph.D. at Johns Hopkins University School of Medicine (1993), where he trained with Dr. Solomon H. Snyder. Prior to joining Lilly, Bredt was Professor of Physiology at the University of California, San Francisco. His research on nitric oxide, glutamate receptor signaling, and synaptic plasticity has yielded more than 200 papers, which have been cited more than 45,000 times in scientific literature. He served on the Medical Advisory Committee for the Muscular Dystrophy Association, was an Established Investigator for the American Heart Association, and was a Presidential Young Investigator for the National Science Foundation.

Bredt has received research awards from the American College of Neuropsychopharmacology, the American Society of Pharmaceuticals and Experimental Therapeutics, the Charles E. Culpeper Foundation, the Arnold and Mabel Beckman Foundation, the EJLB Neuroscience Foundation, the Searle Scholars Award, the Alfred P. Sloan Award, the McKnight Foundation, and the Klingenstein Foundation.